Company:  GERON CORP (GERN)
Form Type:  10-K
Filing Date:  3/12/2020 
CIK:  0000886744 
Address:  919 EAST HILLSDALE BOULEVARD
SUITE 250
 
City, State, Zip:  FOSTER CITY, California 94404 
Telephone:  (650) 473-7700 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$1.54  
Change: 
-0.04 (-2.53%)  
Trade Time: 
02:24 PM EST  
Market Cap: 
$477.96M
Trade GERN now with 

© 2020  
Description of Business
We are a late-stage clinical biopharmaceutical company that is focused on the development and potential commercialization of imetelstat, an innovative therapeutic for hematologic myeloid malignancies. We have global rights to imetelstat, a first-in-class telomerase inhibitor, which was discovered and developed at Geron. We believe targeting telomerase has the potential to inhibit the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. Data reported from our Phase 2/3 clinical trial in lower risk myelodysplastic syndromes, or MDS, indicate imetelstat may induce meaningful and durable transfusion independence and increases in hemoglobin levels, suggesting potential recovery of normal blood cells occurring in the bone marrow, or hematopoiesis.
Register and access this filing in:     
  FORM 10-K
    PART I
      ITEM 1. BUSINESS
        NAME AND TITLE
      ITEM 1A. RISK FACTORS
      ITEM 1B. UNRESOLVED STAFF COMMENTS
      ITEM 2. PROPERTIES
      ITEM 3. LEGAL PROCEEDINGS
      ITEM 4. MINE SAFETY DISCLOSURES
    PART II
      ITEM 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY, RELATED ...
      ITEM 6. SELECTED FINANCIAL DATA
      ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
        Results of Operations
        Liquidity and Capital Resources
      ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT ...
      ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
        REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        CASH FLOW
        NOTES TO FINANCIAL STATEMENTS
          CASH FLOW
      ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ...
      ITEM 9A. CONTROLS AND PROCEDURES
      ITEM 9B. OTHER INFORMATION
    PART III
      ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
      ITEM 11. EXECUTIVE COMPENSATION
      ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND ...
      ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND ...
      ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
    PART IV
      ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
    SIGNATURES
  EXHIBIT 4.1
  EXHIBIT 10.18
  EXHIBIT 10.24
  EXHIBIT 10.33
  EXHIBIT 23.1
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  EXHIBIT 31.1
    CERTIFICATION PURSUANT TO
  EXHIBIT 31.2
    CERTIFICATION PURSUANT TO
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO
  EXHIBIT 32.2
    CERTIFICATION PURSUANT TO